Preclinical data have highlighted a completely different mutational background in melanoma V600K with the overexpression of c-KIT, the inhibition of multiple proapoptotic pathways and a reduced dependence on the ERK/MAPK pathway [23,24,25]. This evidence concerns the gene KIT and melanoma.